1. Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer

3. Immunotherapy in Cancer

4. Checkpoint Inhibitors

5. CTLA4 in Immune Cell Deactivation

6. PD-1/PD-L1 in the Immune Response

7. Biomarkers in Immunotherapy

8. Checkpoint Inhibitors AEs and Response Patterns

9. Checkpoint Inhibitors Evaluating Response

10. Patient Selection for Immunotherapy

11. Checkpoint Inhibitors in Breast Cancer

12. Why Nab-Paclitaxel?

13. JAVELIN (phase 1b): Avelumab in Locally Advanced or mBC

14. KEYNOTE-028 (phase 1b) Pembrolizumab -- Primary Endpoint ORR

15. KEYNOTE-028 (Phase 1b) Pembrolizumab -- Results

16. Future Directions

17. Abbreviations

18. Abbreviations (cont)